-
- Marc Cartellieri
- Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstraße 74, 01307 Dresden, Germany
-
- Michael Bachmann
- Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstraße 74, 01307 Dresden, Germany
-
- Anja Feldmann
- Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstraße 74, 01307 Dresden, Germany
-
- Claudia Bippes
- Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstraße 74, 01307 Dresden, Germany
-
- Slava Stamova
- Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstraße 74, 01307 Dresden, Germany
-
- Rebekka Wehner
- Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstraße 74, 01307 Dresden, Germany
-
- Achim Temme
- Center for Regenerative Therapies Dresden, Tatzberg 47-49, 01307 Dresden, Germany
-
- Marc Schmitz
- Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstraße 74, 01307 Dresden, Germany
説明
<jats:p><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mtext>CD</mml:mtext><mml:msup><mml:mn>4</mml:mn><mml:mo>+</mml:mo></mml:msup></mml:math>and<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mtext>CD</mml:mtext><mml:msup><mml:mn>8</mml:mn><mml:mo>+</mml:mo></mml:msup></mml:math>T lymphocytes are powerful components of adaptive immunity, which essentially contribute to the elimination of tumors. Due to their cytotoxic capacity, T cells emerged as attractive candidates for specific immunotherapy of cancer. A promising approach is the genetic modification of T cells with chimeric antigen receptors (CARs). First generation CARs consist of a binding moiety specifically recognizing a tumor cell surface antigen and a lymphocyte activating signaling chain. The CAR-mediated recognition induces cytokine production and tumor-directed cytotoxicity of T cells. Second and third generation CARs include signal sequences from various costimulatory molecules resulting in enhanced T-cell persistence and sustained antitumor reaction. Clinical trials revealed that the adoptive transfer of T cells engineered with first generation CARs represents a feasible concept for the induction of clinical responses in some tumor patients. However, further improvement is required, which may be achieved by second or third generation CAR-engrafted T cells.</jats:p>
収録刊行物
-
- Journal of Biomedicine and Biotechnology
-
Journal of Biomedicine and Biotechnology 2010 1-13, 2010
Hindawi Limited
